// App-Quantinova.ai

LBSU-1080 : Empagliflozin (EMPA) for ?76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)

Researchers

Presenter

  • Christopher Simon Kovacs

Principal Investigators

  • Veeraswamy Seshiah

  • Ludwig Merker

  • Anita Vedel Christiansen

  • Flavien Roux

  • Afshin Salsali

  • Gabriel Kim

  • Peter Stella

  • Hans-Juergen Woerle

  • Uli C Broedl

Medical Centers

  • Diabetes Care and Research Institute, Chennai, India

  • Mem Univ of Newfoundland, St Johns, Canada

  • Diabetes- und Nierenzentrum, Dormagen, Germany

Locations

  • Canada

  • India

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Urology

Disease

  • Urinary tract infections

  • Type 2 diabetes mellitus

  • Diabetes

  • Obesity

Biomarkers

  • GC Vitamin D Binding Protein

  • Hemoglobin A1c

  • Sex hormone binding globulin

Drug/Treatment

  • metformin HCl + pioglitazone

  • BI-10773

  • Pioglitazone

  • Actoplus Met XR extended-release tablet

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved